Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov 10;1(1):29-34.
doi: 10.5306/wjco.v1.i1.29.

Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation

Luis F Porrata  1 , Svetomir N Markovic
Affiliations

Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation

Luis F Porrata et al. World J Clin Oncol. .

Abstract

The infused stem cell autograft in autologous stem cell transplantation (ASCT) has been viewed mainly as hematologic rescue from the myelosuppressive side effect of conditioning regimens. However, recent reports have shown that the immune effector cells collected at the same time as the stem cells can produce an autologous graft-versus-tumor effect, similar to the graft-versus-tumor effect seen in allogeneic stem cell transplantation without the detrimental effects of graft-versus-host disease. In this article, we review the different immune effector cells collected and infused from the stem cell autograft and their association with clinical outcome post-ASCT, suggesting that ASCT can be viewed not only as a therapeutic maneuver to recover bone marrow function after deliver high-dose chemotherapy, but also as an adoptive immunotherapeutic intervention capable of eradicating residual tumor cells in patients with cancer.

Keywords: Adoptive immunotherapy; Autograft; Autologous graft versus tumor effect.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the role of high-dose chemotherapy and infused autograft immune effector cells in the eradication of tumor cells post-autologous stem cell transplantation. The effects of high-dose chemotherapy (HDC) include tumor burden reduction and the release of tumor antigens. The infused autograft immune effectors cells include dendritic cells (DCs) that can recognize tumor antigens to priming infused autograft CD4+ T-cells, which in turn, activate infused autograft cytotoxic CD8+ T-cells to target tumor cells. The innate immune response component from the autograft is performed by the infused natural killer (NK) cells that can recognize tumor cells and NK cells anti-tumor function can be enhance with the help of DCs.
See this image and copyright information in PMC

References

    1. Porrata LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clin Exp Med. 2004;4:78–85. - PubMed
    1. Porter DL. The graft-versus-tumor potential of allogeneic cell therapy: an update on donor leukocyte infusions and nonmyeloablative allogeneic stem cell transplantation. J Hematother Stem Cell Res. 2001;10:465–480. - PubMed
    1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385–389. - PubMed
    1. Freytes CO, Lazarus HM. Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft? Bone Marrow Transplant. 2009;44:559–569. - PubMed
    1. Hogan WJ, Storb R. Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease. Immunol Res. 2003;28:1–11. - PubMed